Mehr lesen
This volume gives an overview ofstate of the art technologies and future developments in the field ofpreclinical pharmaceutical research. A balanced mix of experts from academiaand industry give insight in selected new developments in the drug discoverypathway. The topics cover the different parts of the drug discovery process,starting with new developments in the target identification and validationarea. The lead generation part as a next step focuses on the requirements andtechnologies to identify new small molecules as lead compounds for furtheroptimization; in a second section the technologies to identify biologics asleads are addressed. The final part focuses on the pharmacological models andtechnologies to characterize new compounds and the impact of biomarkers to facilitatethe transfer of drug candidates into the development phase.
Inhaltsverzeichnis
Preface.-Part 1. Historical View.- Drug discovery in the past and today.Part 2. Target Discovery.- Emerging target families:intractable targets. In vivo target validation especially for biologicaltargets. HR RNAi/High Content analysis.- Part 3. Lead generation and Optimization.- Sources for leads: natural products,libraries. Screening: assays, readout, technology. Impact of structuralbiology, fragment based screening/Virtual screening. Predictive in silico toolsof compound properties. High throughput synthesis. New compound classes:Protein-Protein Interaction. Sources for biological leads/Screening ofbiologicals.- Part 4. Test systems forEfficacy and Safety.- In vitro/ Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impactof biomarkers/personalized medicine. Simulating in vivo drug effects.
Über den Autor / die Autorin
Dr. Ulrich Nielsch, Bayer Pharma AG,Wuppertal, GermanyDr. Ulrike Fuhrmann, Bayer Pharma AG, Berlin, GermanyProf. Dr. Stefan Jaroch, Bayer Pharma AG, Berlin, Germany
Zusammenfassung
This volume gives an overview of
state of the art technologies and future developments in the field of
preclinical pharmaceutical research. A balanced mix of experts from academia
and industry give insight in selected new developments in the drug discovery
pathway. The topics cover the different parts of the drug discovery process,
starting with new developments in the target identification and validation
area. The lead generation part as a next step focuses on the requirements and
technologies to identify new small molecules as lead compounds for further
optimization; in a second section the technologies to identify biologics as
leads are addressed. The final part focuses on the pharmacological models and
technologies to characterize new compounds and the impact of biomarkers to facilitate
the transfer of drug candidates into the development phase.
